Halozyme Therapeutics (HALO) Inventory (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Inventory of $155.5 million for Q1 2026, down 5.7% year-over-year from $164.9 million in Q1 2025, and down 11.9% quarter-over-quarter from $176.5 million in Q4 2025.
Halozyme Therapeutics (HALO) Inventory (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Inventory for 17 consecutive years, with $155.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Inventory fell 5.7% year-over-year to $155.5 million; the TTM figure through Mar 2026 stood at $155.5 million (down 5.7% YoY), while the FY2025 annual figure was $176.5 million, up 24.4% from the prior year.
- Inventory retreated to $155.5 million in Q1 2026 per HALO's latest filing, from $176.5 million in the prior quarter.
- Across five years, Inventory topped out at $185.8 million in Q3 2025 and bottomed at $47.8 million in Q1 2022.
- Historically, Inventory has averaged $135.9 million across 5 years, with a median of $132.4 million in 2023.
- Annual changes were most pronounced in 2022 — Inventory slipped 18.14% — and 2023, when it jumped 125.12%.
- Halozyme Therapeutics' Inventory stood at $100.1 million in 2022, then increased by 27.44% to $127.6 million in 2023, then grew by 11.17% to $141.9 million in 2024, then gained by 24.4% to $176.5 million in 2025, then decreased by 11.9% to $155.5 million in 2026.
- Business Quant data shows HALO's Inventory at $155.5 million in Q1 2026, $176.5 million in Q4 2025, and $185.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.08 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 371.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 732.60 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 358,916.96 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 97.11 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 142.38 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 137.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.14 Mn |
| Mar 31, 2026 | 155.47 Mn |
| Dec 31, 2025 | 176.48 Mn |
| Sep 30, 2025 | 185.80 Mn |
| Jun 30, 2025 | 181.51 Mn |
| Mar 31, 2025 | 164.87 Mn |
| Dec 31, 2024 | 141.86 Mn |
| Sep 30, 2024 | 131.41 Mn |
| Jun 30, 2024 | 159.31 Mn |
| Mar 31, 2024 | 168.54 Mn |
| Dec 31, 2023 | 127.60 Mn |
| Sep 30, 2023 | 128.92 Mn |
| Jun 30, 2023 | 132.41 Mn |
| Mar 31, 2023 | 107.52 Mn |
| Dec 31, 2022 | 100.12 Mn |
| Sep 30, 2022 | 103.28 Mn |
| Jun 30, 2022 | 97.62 Mn |
| Mar 31, 2022 | 47.76 Mn |
| Dec 31, 2021 | 53.91 Mn |
| Sep 30, 2021 | 55.98 Mn |